Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) traded up 5.1% on Tuesday . The stock traded as high as $0.50 and last traded at $0.50. 768,456 shares changed hands during trading, an increase of 17% from the average session volume of 658,570 shares. The stock had previously closed at $0.48.

Separately, Maxim Group restated a “buy” rating and set a $4.00 price target on shares of ContraVir Pharmaceuticals in a report on Thursday, August 24th.

The firm has a 50 day moving average of $0.53 and a 200-day moving average of $0.85. The stock’s market cap is $31.55 million.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Teachers Advisors LLC grew its position in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 298,781 shares of the biopharmaceutical company’s stock after purchasing an additional 8,862 shares during the quarter. Teachers Advisors LLC owned approximately 0.48% of ContraVir Pharmaceuticals worth $1,820,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ContraVir Pharmaceuticals Inc (CTRV) Trading 5.1% Higher” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.watchlistnews.com/contravir-pharmaceuticals-inc-ctrv-trading-5-1-higher/1577478.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.